Literature DB >> 2168876

Structurally based, selective interaction of arsenite with steroid receptors.

S Lopez1, Y Miyashita, S S Simons.   

Abstract

Steroid binding to cognate receptors is of high affinity. However, due to the appreciable homologies in the steroid-binding domains of receptors, this binding is hardly ever totally specific. We have recently obtained evidence that a vicinal dithiol group is involved in steroid binding to glucocorticoid receptors and that these vicinal dithiols are two of the three cysteines in the 16-kDa steroid-binding core. We now report that a comparison of the placement of cysteines in the comparable region of other receptors revealed a lack of similarly closely spaced thiols, which led to the prediction that arsenite would be totally selective in its interaction with glucocorticoid receptors. In fact, 100 microM arsenite inhibited all steroid binding to glucocorticoid receptors while having no effect on the binding of androgen, estrogen, mineralocorticoid, or progesterone receptors. Such total selectivity is not seen for selenite, which is another very potent inhibitor of glucocorticoid binding. This is the first report of absolute selectivity among steroid receptors that is based upon a known structural feature of the receptor protein. This selectivity of arsenite provides the easiest method to date for distinguishing between glucocorticoid and mineralocorticoid receptors and for selectively blocking steroid binding to glucocorticoid receptors in the assays of other receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168876

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Arsenic disruption of steroid receptor gene activation: Complex dose-response effects are shared by several steroid receptors.

Authors:  Jack E Bodwell; Julie A Gosse; Athena P Nomikos; Joshua W Hamilton
Journal:  Chem Res Toxicol       Date:  2006-12       Impact factor: 3.739

2.  In utero exposure to arsenite contributes to metabolic and reproductive dysfunction in male offspring of CD-1 mice.

Authors:  Karina F Rodriguez; Namya Mellouk; Erica K Ungewitter; Barbara Nicol; Chang Liu; Paula R Brown; Cynthia J Willson; Humphrey H-C Yao
Journal:  Reprod Toxicol       Date:  2020-05-17       Impact factor: 3.143

3.  Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment.

Authors:  I Y Kim; T C Stadtman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 4.  Arsenic carcinogenicity: relevance of c-Src activation.

Authors:  Petia P Simeonova; Michael I Luster
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

5.  Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.

Authors:  Adena E Rosenblatt; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2009-01-08

Review 6.  Modulation of nuclear receptor function by cellular redox poise.

Authors:  Eric L Carter; Stephen W Ragsdale
Journal:  J Inorg Biochem       Date:  2014-01-21       Impact factor: 4.155

Review 7.  Arsenic binding to proteins.

Authors:  Shengwen Shen; Xing-Fang Li; William R Cullen; Michael Weinfeld; X Chris Le
Journal:  Chem Rev       Date:  2013-06-28       Impact factor: 60.622

Review 8.  The glucocorticoid receptor: a revisited target for toxins.

Authors:  Jeanette I Webster Marketon; Esther M Sternberg
Journal:  Toxins (Basel)       Date:  2010-06-09       Impact factor: 4.546

9.  Arsenic alters the function of the glucocorticoid receptor as a transcription factor.

Authors:  R C Kaltreider; A M Davis; J P Lariviere; J W Hamilton
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

10.  Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid.

Authors:  David S Paul; Anne W Harmon; Vicenta Devesa; David J Thomas; Miroslav Stýblo
Journal:  Environ Health Perspect       Date:  2007-01-29       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.